Evidence map›Paper›PMID 29029412›Full record

ArticleOncotarget2017

The value of phosphohistone H3 as a proliferation marker for evaluating invasive breast cancers: A comparative study with Ki67.

Ji-Ye Kim, Hyang Sook Jeong, Taek Chung, Moonsik Kim, Ji Hee Lee, Woo Hee Jung, Ja Seung Koo

Abstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. N2B27 media formulations influence gastruloid development.Development (Cambridge, England) · 2025
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. bioRxiv : the preprint server for biology · 2024
    Article
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ji-Ye KimDepartment of Pathology and Translational Genomics, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea.
Hyang Sook JeongDepartment of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Taek ChungDepartment of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Moonsik KimDepartment of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Ji Hee LeeDepartment of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Woo Hee JungDepartment of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
Ja Seung KooDepartment of Pathology, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEstablished measurements of proliferation in breast cancer are Ki67 and mitotic-activity-index (MAI), with problems in reproducibility and prognostic accuracy. Phosphohistone H3 (PHH3), a relatively novel IHC marker is specific for mitosis with good reproducibility. We hypothesized that PHH3 would be more reproducible and better represent proliferation than Ki67.

resultsPHH3 identified easily-missed mitosis by MAI, as demonstrated by upgrading M grade at diagnosis ( MATERIALS AND

methodsWe compared Ki67 and PHH3 for 218 breast cancer surgical cases diagnosed from 2012 to 2013 at Severance hospital. The most representative invasive breast cancer surgical slides were immunohistochemically stained for Ki67 and PHH3.

conclusionsPoor reproducibility and inadequate representation of proliferation of Ki67 and MAI may be improved by PHH3, allowing better accuracy in breast cancer diagnostics.

Indexed as

invasive breast cancerPHH3prognostic valueproliferationreproducibility

Identifiers

PMID29029412
PMCPMC5630312

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.